Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • ECO
    replied
    Hey there...we keep commercial activities in the Vendor Forum and discourage overt commercial posting...please contact me if you want permission to post in the Vendor Forum. Thanks.

    Originally posted by kushald View Post
    Hi rjones89. You could compare the data from 2 platforms, but for the INDELS. The SNP variants called could be compared. Let me know if you need help with this, if you are interested in analysis of only the SNP variants.

    We (Genotypic Technology - www.genotypic.co.in) are a Genomics services provider based in India. Write to me at [email protected] with your query and we can discuss more on this. I will work out the best possible price for analysis work.

    Thanks.

    Leave a comment:


  • Brian Bushnell
    replied
    Originally posted by rjones89 View Post
    Yes, that is what I am wondering - would it be much better to sequence both on the same platform?
    Yes, it would.

    Leave a comment:


  • NextGenSeq
    replied
    Ion Torrent just released the HiQ chemistry for the Ion Torrent. They claim that the indel problem has been resolved.

    Leave a comment:


  • kushald
    replied
    Hi rjones89. You could compare the data from 2 platforms, but for the INDELS. The SNP variants called could be compared. Let me know if you need help with this, if you are interested in analysis of only the SNP variants.

    We (Genotypic Technology - www.genotypic.co.in) are a Genomics services provider based in India. Write to me at [email protected] with your query and we can discuss more on this. I will work out the best possible price for analysis work.

    Thanks.

    Leave a comment:


  • rjones89
    replied
    Yes, that is what I am wondering - would it be much better to sequence both on the same platform?

    Leave a comment:


  • Brian Bushnell
    replied
    It's certainly possible to generate useful data in this case, but there will be a lot more noise than if everything was the same platform. The biggest issue will probably be not the difference in platforms, but the difference in baits/kits; if the tumor sample has 0 coverage for some gene that has 50x coverage in the control, you won't really know if that's because the gene got deleted, or because the capture was ineffective in that area.

    I suggest you calculate the cost of person-hours spent analyzing this data versus the cost of rerunning on or the other so that all data is from the same platform. It does not make sense to spend $50k chasing down and validating spurious differences that could be wiped out en masse with $1k of sequencing. The alternate platform's data is not wasted in this case, either, as it can increase confidence in variations found (or not found) in the other platform.

    Leave a comment:


  • Compare samples sequenced on Ion Proton and Illumina platform

    Is it possible to compare exome data generated on an Ion Proton with exome data generated on an Illumina platform? I have sequenced germline samples on the proton and have sequenced tumour samples using Illumina and I am wondering if it will be at all possible to compare?

Latest Articles

Collapse

  • seqadmin
    Essential Discoveries and Tools in Epitranscriptomics
    by seqadmin




    The field of epigenetics has traditionally concentrated more on DNA and how changes like methylation and phosphorylation of histones impact gene expression and regulation. However, our increased understanding of RNA modifications and their importance in cellular processes has led to a rise in epitranscriptomics research. “Epitranscriptomics brings together the concepts of epigenetics and gene expression,” explained Adrien Leger, PhD, Principal Research Scientist...
    04-22-2024, 07:01 AM
  • seqadmin
    Current Approaches to Protein Sequencing
    by seqadmin


    Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...
    04-04-2024, 04:25 PM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by seqadmin, Yesterday, 08:47 AM
0 responses
12 views
0 likes
Last Post seqadmin  
Started by seqadmin, 04-11-2024, 12:08 PM
0 responses
60 views
0 likes
Last Post seqadmin  
Started by seqadmin, 04-10-2024, 10:19 PM
0 responses
59 views
0 likes
Last Post seqadmin  
Started by seqadmin, 04-10-2024, 09:21 AM
0 responses
54 views
0 likes
Last Post seqadmin  
Working...
X